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Abstract
Glioblastoma (GBM) is a devastating brain tumor with a poor survival outcome. It is generated and propagated by a
small subpopulation of rare and hierarchically organized cells that share stem-like features with normal stem cells
but, however, appear dysregulated in terms of self-renewal and proliferation and aberrantly differentiate into cells
forming the bulk of the disorganized cancer tissues. The complexity and heterogeneity of human GBMs underlie
the lack of standardized and effective treatments. This study is based on the assumption that available markers
defining cancer stem cells (CSCs) in all GBMs are not conclusive and further work is required to identify the CSC.
We implemented a method to isolate CSCs independently from cell surface markers: four patient-derived GBM
neurospheres containing stem, progenitors, and differentiated cells were labeled with PKH-26 fluorescent dye that
reliably selects for cells that divide at low rate. Through in vitro and in vivo assays, we investigated the growth and
self-renewal properties of the two different compartments of high- and slow-dividing cells. Our data demonstrate
that only slow-dividing cells retain the ability of a long-lasting self-renewal capacity after serial in vitro passaging,
while high-dividing cells eventually exhaust. Moreover, orthotopic transplantation assay revealed that the incidence
of tumors generated by the slow-dividing compartment is significantly higher in the four patient-derived GBM neuro-
spheres analyzed. Importantly, slow-dividing cells feature a population made up of homogeneous stem cells that
sustain tumor growth and therefore represent a viable target for GBM therapy development.
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Introduction
Glioblastoma (GBM; World Health Organization grade IV astro-
cytoma) is the most aggressive and common primary brain tumor.
With a dismal prognosis, GBM is the most challenging tumor to
effectively treat; patients affected by GBM have a life expectancy of
less than 1 year [1]. The most common approach for tackling tumors
abides in the isolation of that population of rare cells that are thought
to reseed cancers after chemotherapy and radiotherapy in hemato-
poietic as well as in solid tumors. Since the leukemia tumor-initiating
cell was first described and characterized [2], the origins of these cells
are still controversial, and their biology is not yet fully elucidated.
Stem cells are defined by their ability to divide asymmetrically,
resulting in the formation of two daughter cells, one of which is
another stem cell and the other one is a committed progenitor capable
of further differentiation and, even if limited, proliferation but lacks
the ability to self-renew. A cancer stem cell (CSC) functions likewise
to sustain the growth and spread of tumors while repopulating the
distinct cell types represented within the tumor.
Tumor heterogeneity represents a paramount feature supporting
tumor robustness and inconclusive therapies. The bulk of malignant
cells in GBM is generated by a rare fraction of self-renewing, multi-
potent tumor-initiating cells (CSCs) able to maintain and propagate
the tumor through their capacity of continued growth and resistance
to chemotherapy and radiotherapy [3–6].
Abbreviations: GBM, glioblastoma; CSCs, cancer stem cells; FACS, fluorescence-
activated cell sorting; MTT, 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide
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Moreover, CSCs are able to reinitiate the tumors following trans-
plantation with the key features of the GBMs from which they derived,
e.g., infiltrative phenotype, hypercellularity, pseudopalisading necrosis,
and angiogenesis.
Processing and isolating the tumor-initiating cells in some tumors,
such as breast, prostate, pancreas, skin, colon, and blood cancer, dem-
onstrated the presence of a slowly cycling and highly tumorigenic cell
fraction [2,4,7–13], while the same approach applied to brain tumors,
and in particular to glioblastomas, manifests a remarkable challenge.
Only little experimental evidence exists so far in glioblastoma. The
demonstration of a small pool of cells slowly dividing and that retains
long-term self-renewal ability was only recently obtained in vivo in a
mouse model of glioblastoma through genetically engineered mice
[14]: The chemotherapeutic drug temozolomide killed the highly
proliferating cells within the tumor but did not eliminate the mostly
dormant cells accountable for new bursts of tumor growth when
therapy was stopped. Recently, it has also been reported that a pop-
ulation of dye-retaining brain tumor cells is able to generate GBMs in
immunocompromised mice [15].
Although several markers are enlightening and/or significant for
brain tumor stem cell identification, the segregation of universal spe-
cific markers suitable to pinpoint this tumor population represent-
ing clinically relevant target is still an unachievable goal. Most
current treatments target rapidly dividing cells that generally constitute
the non–stem cell component of tumors, leaving the quiescent, rather
slow-dividing, stem cells to reinitiate the tumor. The slow-dividing
population holds the ability to self-renew and to revert to the quiescent
state to maintain the pool, while the fast-dividing majority population
undergoes a limited but rapid replication and will eventually exhaust.
The isolation of a pure population of slow-dividingCSCswill serve as a
valuable tool to allow the development of new therapeutic strategies to
target the tumor-initiating cell compartment in patients with brain cancer.
In this study, we used PKH-26 fluorescent dye to identify and iso-
late a slow-cycling subpopulation responsible for tumor growth and
progression in human GBMs. Following the binding to the cell mem-
brane, the fluorescent dye is equally distributed between daughter
cells upon division, leading to the halving of the fluorescence intensity
with every cell division. The intensity of PKH-26 staining correlates
with the cell division and then discriminates the highly cycling from
the slowly dividing cells (putative stem cells).
Our findings suggest the application of a marker-independent
method on GBM-derived neurospheres isolated from patients to iso-
late a small homogeneous slow-dividing population capable of long-
term self-renewal and tumor maintenance and progression out of a
tumoral bulk with proliferative heterogeneity.
Materials and Methods
Preparation of Cell Suspensions from Patient GBM
This study was approved by the Ethical Committee for human
experimentation of the European Institute of Oncology, and all
patients signed an approved consent document before surgery. Surgical
specimens of tumors were collected at the Neurosurgery Department,
Istituto Neurologico Carlo Besta (Milan, Italy), and tissue fragments
without necrotic areas were processed. The tissue was mechanically
dissociated into single-cell suspension with papain (2 mg/ml;
Worthington Biochemical, Lakewood, NJ; http://worthington-biochem.
com) at 37°C for 2 hours.
The GBM samples collected in our laboratory were classified in
the three molecular subtypes defined on the basis of gene expression
profile that has been previously described [16,17]. The GBM-derived
neurospheres used for this study were derived from different GBM
classes (i.e., hGBM#7 and hGBM#9 classified as mesenchymal sub-
type and hGBM#8 and hGBM#18 as proneural subtype).
Neurosphere Culture
Neurosphere culture was maintained in Dulbecco’s modified Eagle’s
medium/Ham’s F12 nutrient mixture (DMEM/F12) supplemented
with B27 supplement (Life Technologies, Paisley, United Kingdom;
www.invitrogen. com), 20 ng/ml epidermal growth factor, 10 ng/ml
basic fibroblast growth factor (PeproTech, Rocky Hill, NJ; http://
www.peprotech.com), and 0.0002% heparin (Sigma-Aldrich, St Louis,
MO; http://www.sigmaaldrich.com) at 37°C in a 5% CO2 humidified
incubator, as previously described. All cultures were passaged by
mechanical dissociation of the spheres, and the cells were seeded at a
density of 104 cells/cm2. Cell growth was measured by seeding the cells
in 96-well plates (2000 cells/well) in DMEM/F12 complete medium
and using the CellTiter 96 AQueous Non-Radioactive Cell Prolifera-
tion Assay (Promega, Madison, WI; http://www.promega.com).
PKH-26 Assay
Human primary GBM cells were stained for 5 minutes with
1:2000 PKH-26 dye (Sigma), blocked with 1% BSA, washed twice,
and plated to obtain primary neurospheres that are then passaged for
2 to 3 weeks to allow adequate time for cell division and PKH-26
dilution. Fluorescence-activated cell sorting (FACS/sorting) was per-
formed on single-cell suspensions 2 weeks after labeling using a
FACS Vantage SE Flow Cytometer (BD Biosciences, Franklin Lakes,
NJ) to obtain PKH-positive (PKH-Pos) and PKH-negative (PKH-
Neg) cells. The cells were then isolated according to their label inten-
sity: The brightest cells (1–3% of the entire population) represent the
stem cells characterized by a mean fluorescence compatible with very
few cycles of cell divisions. Purity of sorted populations was verified
by flow cytometry.
FACS/Sorting Analysis
Cells labeled with PKH-26 were subjected to FACS/sorting anal-
ysis with a FACS Vantage SE Flow Cytometer (BD Biosciences;
http://bdbiosciences.com) to yield PKH-Pos (≤3% of the entire
population) and PKH-Neg (≤70% of the cells analyzed) cells. After
gating to eliminate debris and dead cells, additional gates were drawn
in the PKH-26 channel and in the forward scatter channel to select
human PKH-Pos cells. Cells showing signal for PKH-26 above the




GBM neurospheres ready for passaging were mechanically dissoci-
ated and seeded in 96-well plates at the density of 3000 cells per well.
3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT,
50 mg/ml) was added, and after a 4-hour incubation, crystals were
dissolved in DMSO and added to the wells. Cell viability was evaluated
by CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay
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(Promega; http://www.promega.com). Three independent replicates
were considered for each experiment.
Clonogenic Assay
The clonogenic efficiencywas analyzed by seeding humanGBMneuro-
spheres at a low density in methylcellulose whose viscous composition
does not allow cell aggregation. To evaluate the clonogenic capacity,
immediately after sorting analysis, PKH-Pos, PKH-Neg, and unsorted
cells were resuspended in DMEM/F12 with methylcellulose (StemCell
Technologies, Vancouver, British Columbia; http://www.stemcell.
com) and seeded in a 35-mm culture plate (100 cells/cm2). Reported
numbers represent a minimum of three plates per condition. Ten to
fifteen days after plating, neurospheres containingmore than 20 cells were
scored: The ratio between neurospheres formed and number of single
cells plated corresponds to the percentage of neural stem cells in the plate.
Replating Procedure
Soon after clone dissociation and seeding at a low density in
methylcellulose, both PKH-Pos and PKH-Neg cells are able to effi-
ciently clone. The investigation of a possible progressive decline of
this capability due to subsequent subculturing was carried out.
Sorted single cells were seeded in methylcellulose plates and allowed
to form colonies for 2 weeks. Representative clones from each pop-
ulation were picked with a Gilson tip, dissociated, and then reseeded
in the stem cell medium and methylcellulose. We serially passaged
GBM-derived neurospheres from five different patients up to the ter-
tiary neurospheres to estimate the overall clonogenic efficiency of
PKH-Pos cells compared to PKH-Neg cells. After several serial pas-
saging on the viscous medium, PKH-Neg cells exhibited limited pro-
liferative potential exhausting, while PKH-Pos generated a large
number of progeny even if this population showed a slight reduction
in self-renewal potential (Figure 2D; *P < .05).
In Vivo Limiting Dilution Transplantation Assay
FACS/sorting was applied on GBM single-cell suspensions to sort
the cells into PKH-Pos and PKH-Neg cells 2 weeks after labeling.
Different cell concentrations (from 105 to 10 cells) of the subpopu-
lations obtained post-sorting and the unsorted cells were resuspended
in 2 μl of phosphate-buffered saline (PBS) and stereotaxically in-
jected into the nucleus caudatus (coordinates from bregma: 1 mm
posterior, 3 mm left lateral, and 3.5 mm in depth) of 5-week-old
female nu/nu CD1 mice (Charles River, Wilmington, MA; http://
www.criver.com). In vivo experiments in CD-1 nude mice were
performed in accordance with the Italian laws (D.L.vo 116/92 and
following additions), which enforce EU 86/609 Directive (Council
Directive 86/609/EEC of 24 November 1986 on the approximation
of laws, regulations and administrative provisions of the Member
States regarding the protection of animals used for experimental
and other scientific purposes). The mice were maintained until
development of neurologic signs, and the brains of killed mice
were collected.
Immunohistochemistry
Xenografted mouse brains were formalin-fixed and paraffin-
embedded according to established procedures. Each brain was sliced
into several 5-μm coronal sections and placed onto polysine slides
(Thermo Scientific, Waltham, MA). Sections were cut, deparaf-
finized with xylene, rehydrated in a graded alcohol series, and stained
in Mayer’s hematoxylin and eosin (H&E)–phloxine B solution.
For immunohistochemistry (IHC), tissue endogenous peroxidases
were blocked with 3% hydrogen peroxide and antigen retrieval was
carried out in sodium citrate (0.01 M, pH 6.0) in a water bath (at
95°C for 55 minutes). Paraffin-embedded sections were blocked
with a PBS solution containing 2% goat serum and 1% BSA for
120 minutes and incubated overnight in humidified chambers with
primary antibodies: human nuclei (monoclonal mouse, 1:1000;
Millipore, Billerica, MA), Olig2 (goat polyclonal, 1:500; Santa
Cruz Biotechnology, Dallas, TX), Sox2 (rabbit polyclonal, 1:50;
StemCell Technologies), human Nestin (mouse monoclonal, 1:200;
Chemicon Millipore), human CD31 (mouse monoclonal, 1:40; Dako,
Carpinteria, CA), CD15 (mouse monoclonal, 1:100; BD Pharmigen,
San Jose, CA), CD133 (mouse monoclonal, 1:100; Miltenyi, Bergisch
Gladbach, Germany), and Ki-67 (mouse monoclonal, 1:50; Millipore).
Tissue sections were washed in PBS and incubated with a second-
ary biotinylated antibody (1:200; Vector Labs, Burlingame, CA) for
1 hour. Antibody binding was detected using a VECTASTAIN Elite
Avidin-Biotin Complex Peroxidase Kit following the manufacturer’s
instructions. All sections were counterstained with Mayer’s hematoxylin
and visualized using a bright-field microscope.
Statistical Analysis
Statistical analysis was performed using Statistical Package for
Social Science software. Significance of differences for all parametric
variables has been tested by means of analysis of variance (ANOVA)
or generalized linear models (GLMs). Data are graphed as mean +
95% confidence intervals. Differences were considered “statistically
significant” when *P < .05, **P < .001, and ***P < .0001.
Results
Isolation of a Slow-Dividing Cell Population Present in
GBM-Derived Neurospheres
We have established neurosphere cultures from GBM patient
specimens by culturing freshly dissociated cells in conditions com-
monly used to culture neural stem cells [16,18,19]. To be defined
as cancer stem/progenitor cell populations, these cells are required
to be clonogenic in vitro, to express stem cell markers (like Olig2
or Sox2) [20,21], to be capable of neuronal and/or glial differentia-
tion, and to be tumorigenic in vivo, generating xenograft tumors that
recapitulate the biologic features of the parental GBM.
We performed proliferative assays based on the property of the PKH-
26 fluorescent dye to bind cell membranes and to segregate in daughter
cells after each cell division, such that intensity of staining correlates with
the number of prior cell divisions at the single-cell level [22].
We examined a series of four GBM patient–derived neurospheres
cultured for few passages to identify and isolate slow-dividing puta-
tive stem cells, since the neurospheres are composed of a mixed pop-
ulation of stem, progenitors, and differentiated cells. FACS/sorting
analyses of the two different compartments of slow- and high-dividing
cells (making up most of the neurospheres) were carried out 2 weeks
after dye labeling. In Figure 1A, examples of typical FACS/sorting
PKH-stained cell profiles derived from two different patients are rep-
resented. PKH-Pos (slow-dividing) cells are defined as the ∼1% to
3% most fluorescent cells, characterized by a mean fluorescence
compatible with very few cycles of cell divisions, while PKH-Neg cells
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represent up to 70% of highly dividing gated cells. The two fractions
(PKH-Pos and PKH-Neg cells) were immediately expanded in liquid
culture after sorting, and the growth was assessed by MTT assay. We
found reduced cellular growth kinetics of PKH-Pos cells in all patient-
derived GBM neurospheres analyzed (Figure 1B; **P < .001 with
ANOVA among cell fractions). These results suggest that the PKH-
Pos cells are not quiescent but are rather capable to divide at low rate.
Quantitative Clonal Analysis
To further characterize the slowly dividing cell fraction retaining
the dye (PKH-Pos) inside the membrane, we analyzed its clonogenic
potential compared to the negative counterpart and the total popu-
lation (pre-sorting; Figure 2A) by methylcellulose assay. Following
fractioning of established neurosphere cultures through FACS,
clonogenic capacity analysis was performed by counting single clones
obtained after 15 days of culture, and the clonogenic cells were cal-
culated as the percentage of the total number of seeded cells (up to
3000 cells) on 35-mm petri dishes. We observed that both the cell
fractions retaining the dye (PKH-Pos) and the negative counterpart
(PKH-Neg) were able to form expandable neurospheres, but the
clonogenic efficiency was considerably variable: The cells retaining
the PKH-26 dye showed a significant increased capacity to form
spheres (ranging from 7.5% for hGBM#7 to 25.8% for hGBM#18)
compared to the fast proliferating sibling cells and the total popula-
tion. The greater clonogenic capacity of PKH-Pos cells might be jus-
tified by the urge to self-maintain and to generate a more frequently
dividing population, while the PKH-Neg fraction, however, exhibited
a lower clonogenic ability since it has already made an extensive num-
ber of cycles toward the differentiation (see also Figure W1).
We found a divergence in size of the PKH-Neg cell–derived clones
and PKH-Pos cell–derived clones: The diameter was 30% bigger in
spheres composed by PKH-Pos cells (Figure 2B; **P < .0001 using
unpaired t test with t = 9.585 and df = 77). The number of the cells
composing the neurospheres was about three times more in neuro-
spheres derived fromPKH-Pos cells (data not shown). The neurosphere-
forming process ability was assessed in terms of fluctuation in size and
number of clones 2 weeks after plating in methylcellulose at low density
for the PKH-Pos, PKH-Neg, and the entire population (unsorted).
The proportion of larger neurospheres (with a diameter bigger than
200 μm) fell in the long-term self-renewable PKH-Pos population.
Clones with a diameter smaller than 50 μm were represented in greater
proportion in the PKH-Neg population and, in a lesser extent, in the
unsorted fraction (Figure 2C ).
We then performed experiments to evaluate the clonogenic capac-
ity of PKH-Pos, PKH-Neg, and unsorted cells: Dissociated cells were
serially passaged up to the tertiary neurospheres to estimate the ex-
tensive clonogenic efficiency of PKH-Pos cells compared to PKH-
Neg cells in all the patients analyzed. After several serial passaging
on the viscous medium, PKH-Neg cells exhibited limited prolifera-
tive potential exhausting, while PKH-Pos cells still generated a large
number of progeny (Figure 2D; *P < .05 with Tukey post-hoc test).
This is consistent with the definition of stem cell (uncommitted cell
that divides repeatedly and indefinitely while maintaining the po-
tency to generate differentiated cell types) and progenitor, that is, a
cell with a limited division capacity before a change in potency or
overt differentiation.
Carrying out these experiments of neurosphere-forming profi-
ciency, we were able to split off slowly and highly dividing cells
and demonstrate that the former were able to produce large colonies
Figure 1. Flow cytometric cell sorting of PKH-26–positive and PKH-26–negative cells and their growth kinetics. (A) Schematic represen-
tation of PKH-26 cell labeling and culture expansion. After gating to eliminate debris and dead cells, additional gates were drawn to
select PKH-Pos cells. Representative flow cytometry plots depict the gating strategy for collections of PKH-Pos (1–3%) and PKH-Neg
cells (up to 70%; right panel) and not stained cells (left panel). The scale bar in boxed areas represents 20 μm. (B) The growth properties
of PKH-Pos and PKH-Neg cells and unsorted cells from hGBM#7, hGBM#8, hGBM#9, and hGBM#18 were investigated through MTT
assay. Cell growth was measured every 24 hours for 7 days. SD bars are shown for each measurement. **P< .01 with one-way ANOVA
with Bonferroni correction for multiple comparisons.
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with a greater self-renewal potential allowing several consecutive
“pick and replate,” while the negative fraction gave rise predominantly
to small clones derived from cells that do not exhibit stem cell criteria.
These results suggest that PKH-Neg cells contain mostly progenitor
cells that actively divide for few cycles and then exhaust, whereas the
slow-cycling cell pool (PKH-Pos) remains relatively quiescent to
expand in number.
PKH-Pos Cells Exhibit Greater In Vivo Tumor-Initiating
Capacity and Stem Cell Frequency
We carried out an orthotopic transplantation assay stereotaxically
injecting dissociated neurospheres derived from four different patients
(hGBM#7, hGBM#8, hGBM#9, and hGBM#18) in the brain of
nude mice (n = 3 minimum per group) to test their ability to generate
xenograft tumors recapitulating the biologic and genomic features of
the parental GBM.
To assess the number of cells required to generate tumors in vivo, we
intracerebrally injected the PKH-Pos, PKH-Neg, and unsorted popu-
lations at different concentrations (from 100,000 cells to 10 cells).
The 100% of mice injected with 105 or 104 cells derived from the
three subpopulations developed tumors with no differences in sur-
vival. PKH-Pos cells engrafted with lower cell doses (100 or 10 cells)
formed tumors in all the injected animals, while PKH-Neg cells
generated tumors only at low frequency or not at all (as shown by
H&E and IHC analysis; Figures W2, W3, and W4), with a statisti-
cally significant difference (*P < .0001 for both doses; Table 1).
Using the ELDA algorithm (http://bioinf.wehi.edu.au/software/
elda/), we calculated the CSC frequency in the tumors derived from
the three cell populations transplanted: The analysis showed a signif-
icantly higher CSC frequency (1/1 to 1/8) in the positive fraction
compared to the negative counterpart (1/154 to 1/4802). The un-
sorted population of all the patients analyzed showed an intermediate
D
Figure 2. Distinct clonogenic efficiency of the PKH-Pos and PKH-Neg cell compartments. (A) Bars represent the clonogenic potential of
PKH-Pos cells (ranging from 7.5% for hGBM#7 to 25.8% for hGBM#18) collected immediately after sorting (post sorting) and compared
to unsorted cells and the negative counterpart. All cells were grown in methylcellulose for 15 days, and then each plate was examined
under a light microscope, and the total number of formed neurospheres was determined. *P < .05; **P < .01 with one-way ANOVA
with Bonferroni correction for multiple comparisons. (B) The graph depicts the characteristic discrepancy in spheres’ size between neuro-
spheres derived from PKH-Pos cells and PKH-Neg cells and assessed after 2 weeks of growth at low density in methylcellulose substrate.
The data are the means ± SD from four patients (n = 60 spheres for each fraction for each patient; **P < .01). The scale bar represents
100 μm. (C) The panel shows the fluctuation of spheres’ size among all the studied neurospheres. Black represents spheres with diameter
from50μmto up to 100μmdistributed among unsorted, PKH-Pos, and PKH-Neg cells, and gray illustrates sphereswith a diameter≥200μm,
while the bars with solid line show the contribution of spheres with a not determined diameter (N.D.). (D) Clonogenic efficiency of GBM cells
after serial replating. Random single clones from both populations were picked up and, after dissociation, consecutively plated for at least
three times in methylcellulose to form new secondary spheres. The majority of the cells die during passaging except for the responsive
sphere-forming cells: The PKH-Neg pool goes down to 0% efficiency, while the PKH-Pos putative stem cells can be indefinitely replated.
Average values derived from six independent experiments/patients were represented. Error bars represent 95% confidence intervals
(*P < .05). GLM plus Tukey post-hoc test was used.
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estimation of CSC frequency. Histologic analysis of tumors that
arose in all mice transplanted with the three cell populations showed
that all the tumors were GBMs according to the World Health
Organization classification and they all were similar in cytoarchitecture,
vascularization, and invasiveness (H&E of brain coronal sections
analyzed with ImageJ software, rsbweb.nih.gov/ij/; Figure W2). After
testing the human origin of injected cells through the antigen human
nuclei, the expression pattern of putative stem cell markers (i.e.,
CD133, CD15, CD31 Sox2, Olig2, and Nestin) was examined and
quantified, but no consistent differences were found in the patients
studied nor among the tumors derived from the three different cell
fractions. Ki-67 expression was also evaluated in the same sections
analyzed by IHC and no differences were found (Figure W3).
Expression of stem cell–associated genes was evaluated in vitro in
PKH-Pos, PKH-Neg, and the total population of all the studied GBM-
derived neurospheres. The putative stem/progenitor cell markers Olig2
and Nestin were enriched in PKH-Pos fraction, while Sox2 showed
statistically significant difference (Figure 3; *P < .05 with paired samples
t test); other markers as CD133 and CD15 were expressed in variable
degrees among the samples.
These results show that both PKH-Pos and PKH-Neg populations
are able to form tumors in vivo, but PKH-Pos cells exhibit higher
in vivo tumor-initiating capacity.
Taking Apart Clonogenic and Tumorigenic Capacity
We analyzed the frequency of stem cells as cells able to form neuro-
spheres in vitro (by methylcellulose assay) and to initiate tumors
in vivo (by limiting dilution assay) in all the patients studied (hGBM#7,
hGBM#8, hGBM#9, and hGBM#18). Interestingly, in the unsorted
and PKH-Neg cell populations, there was a relevant difference in
the stem cell frequency calculated by neurosphere-forming assay and
by in vivo limiting dilution (Figure 4; *P < .05 with Tukey post-hoc
test); CSCs in vitro resulted significantly higher than in vivo. This
finding means that not all the cells able to form neurospheres in vitro
are able to form tumors in vivo. Indeed, we demonstrated by methyl-
cellulose assay that PKH-Neg cells form in vitro small clones that
exhaust after picking and replating, being composed of progenitor cells.
Moreover, the stem cell frequency of PKH-Pos cells was similar in
Table 1. Frequency of CSCs in hGBM#7, hGBM#8, hGBM#9, and hGBM#18 Neurospheres.
Number of Transplanted Cells CSC Frequency (Estimate)
105 104 103 102 10
hGBM#7 Unsorted Incidence 14/14 5/5 6/7 4/9 0/9 1/353
Median survival 47.4 ± 7.3 51.8 ± 7.9 70.7 ± 11.4 60.7 ± 8.8 0 ± 0
PKH-Neg Incidence 8/8 3/3 0/3 0/3 1/433
Median survival 65.6 ± 15.1 65.3 ± 9.6 0 ± 0 0 ± 0
PKH-Pos Incidence 8/8 3/3 4/4 3/4 1/8*
Median survival 63.6 ± 4.5 77 ± 5.2 84.7 ± 14.4 117.3 ± 43.5
hGBM#8 Unsorted Incidence 6/6 8/8 7/7 8/7 2/4 1/100
Median survival 77.7 ± 10.5 84.5 ± 14.3 111.8 ± 5.3 133 ± 9.8 156 ± 4.2
PKH-Neg Incidence 3/3 3/3 3/6 0/3 1/154
Median survival 120 ± 3.5 108.3 ± 6.6 198 ± 37 0 ± 0
PKH-Pos Incidence 3/3 3/3 5/5 3/3 1/1*
Median survival 118.7 ± 19.6 119.7 ± 4.2 130.8 ± 17.2 258.8 ± 79.1
hGBM#9 Unsorted Incidence 5/5 4/4 3/4 2/4 2/4 1/304
Median survival 92.3 ± 10.6 137.6 ± 6.3 183.7 ± 38 166.2 ± 59 243 ± 15.5
PKH-Neg Incidence 3/4 1/4 1/4 0/4 1/4802
Median survival 160 ± 0 233 ± 0 123 ± 0 0 ± 0
PKH-Pos Incidence 4/4 4/4 4/4 4/4 1/1*
Median survival 175.3 ± 35 123.7 ± 20 202.7 ± 9 234.7 ± 19
hGBM#18 Unsorted Incidence 4/4 7/7 6/7 4/6 3/7 1/240
Median survival 66.7 ± 10.3 80.5 ± 10.6 92.3 ± 5.2 148.6 ± 23.5 131.7 ± 10.6
PKH-Neg Incidence 6/6 4/6 2/6 0/6 1/681
Median survival 88.9 ± 8.7 114 ± 8.2 197.5 ± 27.4 0 ± 0
PKH-Pos Incidence 6/6 6/6 6/6 5/6 1/6*
Median survival 121.3 ± 21.5 101.3 ± 4 142.1 ± 8.4 143.1 ± 3.2
Limiting dilution analysis of CSC frequency calculated with ELDA algorithm in unsorted, PKH-Pos, and PKH-Neg cells of four different patients immediately after sorting analysis. Data show the CSC
frequency per transplanted cell (estimate) from the indicated cell groups. In the table, the incidence of tumor formation and the survival time (in days; mean ± SD) of tumor-bearing mice after injection
of hGBM#7, hGBM#8, hGBM#9, and hGBM#18 cells are also indicated. Differences in CSC frequency between the PKH-Pos population and the other two experimental groups are calculated and
resulted statistically significant for *P < .0001.
Figure 3. Gene expression levels in patient-derived neurospheres.
Putative stem-like cell gene expression was quantified by quantita-
tive reverse transcription–polymerase chain reaction in four differ-
ent GBM-derived neurospheres (of hGBM#7, hGBM#8, hGBM#9,
and hGBM#18)withn=5.Experimentswereperformed in triplicate.
Error bars represent 95% confidence intervals (*P < .05). GLM plus
paired samples t test was used.
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in vitro and in vivo studies, demonstrating that the PKH-Pos fraction is
the unique population composed of homogeneous stem cells.
Discussion
Marker-independent Method to Isolate CSCs
Fluorescent labeling has been already used to track and to define the
biology of long-term repopulating hematopoietic stem cells because of
their quiescent nature [22] and, more recently, to purify stem cells
from cultured mammospheres isolated from normal mammary gland
[23]. The skeletal muscle tissue comprises an undifferentiated slow-
dividing cell population with long-term self-renewal ability that is
restricted to the PKH-26 label–retained cell fraction [24].
While a slow-cycling cell compartment highly enriched in tumor-
igenic stem cells has been already described in several solid tumors
such as breast [25], pancreas [26], and melanoma [27], in the human
brain tumors a small subpopulation of slow cycling stem-like cells
driving glioblastoma formation still needs to be identified. A CSC
would function similarly to a normal neural stem cell to sustain
the growth and spread of tumors, repopulating in the meanwhile
the distinct cell types represented within the tumor. However, a
CSC would not be subjected to the same intrinsic and extrinsic con-
trols as normal stem cells.
Several studies report discrepancies on the segregation of universal
markers for CSCs in gliomas mainly due to a lack of uniform layout
for cell sorting and “stemness” determination. Furthermore, the iso-
lation of CSCs implies the identification of possible markers: Here,
we suggest an alternative method based on the functional properties
of the membrane-labeling vital dye PKH-26 to isolate a “pure” pop-
ulation of CSCs.
Slow-dividing Cells Exhibit Indefinite Self-Renewal Capacity
In Vitro
As model system, we chose to use the neurospheres because they
represent a good surrogate for in vitro study of glioma stem and pro-
genitor cells [19,28]. A recent study indicates that in vitro expansion
of GBM stem/progenitor cells as neurospheres does not alter the
differentiation ability and the tumorigenic potential of these cells,
neither their karyotype and gene expression pattern [29].
The label retaining cells make divisions at a slow pace but show a
more clonogenic efficiency compared to the other fractions in all the
patients studied that might be the result of an asymmetric division in
which PKH-26–positive stem cells are slow dividing because they
have to maintain the pool.
To note, the free-floating culture system (MTT assay shown in
Figure 1) allows an indefinite growth for all subpopulations because
it contains a mixed population of cells at various stage of commit-
ment while solid and viscous medium (e.g., methylcellulose) sustains
the growth of a less heterogeneous population, in which only cells
endowed with “stemness” characteristics are able to indefinitely expand.
Surprisingly, the unsorted cell fraction grows faster than the PKH-26–
negative fraction. We can hypothesize that the growth of PKH-26–
negative cells can be influenced by the PKH-26–positive cells within
the bulk population.
It is important to note that clone sizes varied among the colonies
on methylcellulose: While PKH-26–negative cells formed clones
extremely variable in size (diameter smaller than 50 μm and up to
100 μm), PKH-26–positive cells gave rise to clones displaying a signif-
icantly bigger diameter—and in a greater proportion—in all patients
considered, indicating that slow-dividing cells composing neurospheres
identify a homogeneous population. Due to fewer cell divisions com-
pleted, PKH-Pos fractions exhibit an increased number of cells endowed
with “stemness” properties (thenmore prone to cancer), while the PKH-
Neg fraction is mainly composed of progenitor cells set up to a more
advanced stage of differentiation. This cell fraction is made up of cells
at different levels of differentiation: There are cells in immature state,
cells moving toward a more differentiated state, and cells that have
already completed the major part of their life span.
The high heterogeneity in cell population composition present in
each GBM is reflected in a dearth of markers (or pattern of markers)
sufficiently robust to convincingly identify GBM stem cells. In this
study, the expression of the putative stem cell markers Olig2, Nestin,
Sox2, CD133, and CD15 has been analyzed by quantitative reverse
transcription–polymerase chain reaction, and the PKH-Pos cells of
the four human GBM-derived neurospheres investigated showed
an up-regulation of three of five genes that are enriched in CSCs,
though only Sox2 exhibited a difference that is statistically signifi-
cant. These results emphasize the concept that PKH-26–positive
population is enriched of CSCs heterogeneously expressing more
than one putative stem cell marker.
Experiments of consecutive neural colony-forming assay showed
that after plating PKH-26–positive and PKH-26–negative fractions,
only the former was able to produce large colonies with a greater pro-
liferative potential (extensive self-renewal and proliferative potential),
while the negative fraction was exhausted starting from the second
replating. These results reveal that PKH-Neg population is mainly
composed of progenitor cells that have done several cell cycles and are
committed toward a more differentiated state. However, PKH-Pos cells
showed an extended clonogenic efficiency through which it is possible
to maintain the pool of undifferentiated cells and at the same time to
generate early progenitors.
Our results are in accordance with previous experimental data
of clonal studies on semisolid substrate of glioma cells demonstrat-
ing that large colonies contain numerous self-renewed progeny,
suggesting that the cells generating large colonies possess stem cell
characteristics [30,31].
Figure 4. Stem cell frequency calculated in vitro by methylcellulose
assay and in vivo by limiting dilution assay. Comparison of stem
cell frequency calculated by in vivo and in vitro assays in unsorted,
PKH-Pos, and PKH-Neg cell fractions of a pool of four patients.
Results suggest that the PKH-Pos fraction is a unique population
consisting of homogeneous cells, maintaining the same stem cell
frequency when calculated using the neurosphere-forming assay
and the in vivo limiting dilution assay. Error bars represent 95%
confidence intervals (*P < .05). GLM plus Tukey post-hoc test
was used.
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PKH-Pos Cells Exhibit Greater In Vivo Tumor-Initiating
Capacity and Stem Cell Frequency
Through in vivo limiting dilution analysis, we demonstrated that
the stem cell frequency (calculated by the ELDA algorithm) was sig-
nificantly lower in the negative counterpart (1/154 to 1/4802) in
comparison with the label retaining slow-dividing cell proportion
(1:1 to 1:8) in all patients analyzed. Only for the slow-dividing cells
the frequency of stem cells measured in vitro by methylcellulose assay
was similar to that measured in vivo by limiting dilution assay, empha-
sizing the data that PKH-Pos fraction contains a homogeneous popu-
lation of cells. On the contrary, the frequency of stem cells assessed
by methylcellulose assay was higher than the frequency estimated by
in vivo limiting dilution assay for the PKH-Neg cells that indeed
formed in vitro small, exhausting clones. This disparity between clono-
genicity in vitro and tumorigenicity in vivo points out the fact that not
all tumorigenic cells in the PKH-Neg cell fraction are stem cells. In fact,
while PKH-26–positive cells display self-renewal ability in vitro, the
PKH-Neg cells denote self-extinguishing behavior.
Our data are supported by the recent identification in vivo in a
mouse model of glioma of quiescent glioma stem–like cells that prop-
agate tumor growth after chemotherapy [14].
Conclusion
A major conclusion of this investigation is the finding of relatively
quiescent stem-like cells able to expand indefinitely to sustain tumor
growth, and this capacity counteracts proliferating progenitors, a het-
erogeneous pool of cells near the differentiation stage.
Our study demonstrates the feasibility to take advantage of fluo-
rescent dye as PKH-26 to enrich for slow-dividing cells retaining
high capability to self-renew to identify a distinct category of cells that
constitute the tumor.
Therefore, a new approach to GBM therapy might focus on spe-
cific targeting of these populations.
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Figure W1. Proliferation capacity of PKH-Pos and PKH-Neg subpopulations. The growth rate of PKH-Pos and PKH-Neg cells of the four
GBM-derived neurospheres is measured as doubling time of each GBM-derived neurosphere. Immediately after sorting, PKH-Pos and
PKH-Neg cells were incubated for 5 minutes with 1:2000 PKH-26. Dye dilution was identified on the day of loading and 24, 48, 96, 120,
and 144 hours after PKH labeling. On the basis of the fact that PKH-26 intensity decreased every time the cell divides, we calculated the
time to undergo cell division based on the decay rate of PKH intensity using the following formula: 2X = B with X as the number of cell
division and B as the ratio between initial PKH-26 mean fluorescence intensity and final PKH-26 mean fluorescence intensity; thus,
X = logB/log2.
Figure W2. IHC analysis of tumors derived from the injection of unsorted, PKH-Pos, and PKH-Neg populations. Representative images of
H&E and human nuclei antibody staining of coronal sections of brains of immunocompromised mice injected with unsorted, PKH-Pos,
and PKH-Neg cells. Images show that all the brains analyzed were bearing tumors. Human nuclei staining shows that there is no differ-
ence among tumors formed by different cell fractions. Scale bars, 500 μm (H&E and hNuclei) and 50 μm (inset).
Figure W3. IHC analysis of tumor derived from the injections of unsorted, PKH-Pos, and PKH-Neg populations. Olig2, Nestin, Sox2,
CD15, CD133, CD31, and Ki-67 staining on adjacent sections reveal no consistent differences among the tumors derived from the three
different cell fractions. Scale bar, 50 μm.
Figure W4. High capability of PKH-Pos cells to form tumor when injected at low doses. (A) Kaplan-Maier survival graphs of mice injected
with low numbers of PKH-Pos and PKH-Neg cells: The latter population shows a statistically significant delay in tumor formation com-
pared to the PKH-26–positive cell fraction. *P < .05; **P < .01 calculated with log rank test. (B) IHC of xenograft tumors derived from
GBM-derived neurospheres. Representative images of H&E staining of brains of immunocompromised mice implanted with 10 PKH-Pos
cells and 10 PKH-Neg cells. The staining shows that the animals transplanted with as few as10 PKH-Pos cells developed tumors, while
mice injected with 10 PKH-Neg cells did not. Scale bar, 500 μm.
